argenex SE $ARGX Shares Sold by Ritholtz Wealth Management

Ritholtz Wealth Management lowered its stake in argenex SE (NASDAQ:ARGX) by 20.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 715 shares of the company’s stock after selling 182 shares during the period. Ritholtz Wealth Management’s holdings in argenex were worth $394,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of ARGX. Janney Montgomery Scott LLC increased its holdings in shares of argenex by 41.6% in the first quarter. Janney Montgomery Scott LLC now owns 1,141 shares of the company’s stock valued at $675,000 after purchasing an additional 335 shares during the period. Cambridge Investment Research Advisors Inc. acquired a new position in shares of argenex in the first quarter valued at approximately $583,000. Oppenheimer & Co. Inc. increased its holdings in shares of argenex by 10.2% in the first quarter. Oppenheimer & Co. Inc. now owns 915 shares of the company’s stock valued at $542,000 after purchasing an additional 85 shares during the period. Yorktown Management & Research Co Inc acquired a new position in shares of argenex in the first quarter valued at approximately $252,000. Finally, Golden State Wealth Management LLC acquired a new position in shares of argenex in the first quarter valued at approximately $44,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Performance

argenex stock opened at $849.46 on Tuesday. The firm has a market capitalization of $52.30 billion, a price-to-earnings ratio of 43.56, a price-to-earnings-growth ratio of 0.91 and a beta of 0.46. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $855.46. The stock’s fifty day moving average is $738.90 and its two-hundred day moving average is $638.36.

argenex (NASDAQ:ARGX) last posted its earnings results on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.90. The company had revenue of $866.79 million for the quarter, compared to analyst estimates of $776.82 million. argenex had a return on equity of 21.06% and a net margin of 40.98%. As a group, sell-side analysts forecast that argenex SE will post 3.13 EPS for the current fiscal year.

Analysts Set New Price Targets

ARGX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. upped their price objective on argenex from $775.00 to $830.00 and gave the stock an “overweight” rating in a report on Monday, August 4th. HC Wainwright upped their price objective on argenex from $720.00 to $774.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Deutsche Bank Aktiengesellschaft lowered argenex from a “buy” rating to a “hold” rating in a report on Thursday, September 11th. Wells Fargo & Company upped their price objective on argenex from $741.00 to $756.00 and gave the stock an “overweight” rating in a report on Thursday, July 31st. Finally, Jefferies Financial Group set a $818.00 price objective on argenex and gave the stock a “buy” rating in a report on Tuesday, August 26th. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, argenex has a consensus rating of “Buy” and a consensus price target of $817.53.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.